ASX Share rice
Sat 15 May 2021 - 03:47:am (Sydney)

NXS Share Price

NEXT SCIENCE LIMITEDNXSHealth Care Equipment & Services

NXS Company Information

Name:

Next Science Limited

Sector:

Healthcare

Industry:

Drug Manufacturers-Specialty & Generic

Address:

The Zenith Building Tower A Chatswood NSW Australia 2067

Phone:

61 2 8607 5124

MD, CEO & Exec. Director:

Ms. Judith Mitchell M.B.A.

Founder & CTO:

Dr. Matthew Myntti

Chief Financial Officer:

Ms. Jacqueline Butler CA (ICAEW)

Chief Operating Officer:

Mr. Jon Swanson

Chief Commercial Officer:

Mr. Dustin Haines

Company Sec.:

Ms. Gillian Maria Nairn

Company Overview:

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. The company develops its products using its Xbio Technology platform. It offers SURGX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and BACTISURE, a surgical lavage that is used to wash out the surgery site and Intramedullary canal. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site and post-operative infections. It has strategic partnerships with Montana State University Center for Biofilm Engineering, Mayo Clinic, Texas Tech University Clinical Research Institute, Southwest Regional Wound Care Center, University of Florida Department of Otolaryngology, and Jacksonville Center for Clinical Research. Next Science Limited has operations in the United States and Australia. The company was founded in 2012 and is headquartered in Chatswood, Australia.

NXS Share Price Information

Shares Issued:

197.97M

Market Capitalisation:

$333.59M

Revenue (TTM):

$3.44M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.08

Operating Margin (TTM):

$-3.63

Return On Assets (TTM):

$-0.34

Return On Equity (TTM):

$-0.62

Quarterly Revenue Growth (YOY):

0.391

Gross Profit(TTM):

$2.92M

Diluted Earnings Per Share (TTM):

$-0.081

NXS CashFlow Statement

CashFlow Date:

2020-12-31

Investments:

$-891,715.14

Change To Liabilities:

$1.55M

Total Cashflow From Investing Activities:

$-686,799

Net Borrowings:

$-222,609

Net Income:

$-11,912,004

Total Cash From Operating Activities:

$-11,906,644

Depreciation:

$504.47K

Change To Inventory:

$-629,516

Change To Account Receivables:

$-2,097,048

Sale Purchase Of Stock:

$-503,427.68

Capital Expenditures:

$213.24K

NXS Income Statement

Income Date:

2020-12-31

Income Before Tax:

$-15,466,117.89

Net Income:

$-15,466,117.89

Gross Profit:

$3.84M

Operating Income:

$-16,220,207.74

Other Operating Expenses:

$-38,497

Total Revenue:

$4.52M

Cost Of Revenue:

$680.52K

NXS Balance Sheet

Balance Sheet Date:

2020-12-31

Intangible Assets:

$3.03M

Total Liabilities:

$6.14M

Total Stockholder Equity:

$24.56M

Other Current Liabilities:

$2.40M

Total Assets:

$30.69M

Common Stock:

$101.28M

Retained Earnings:

$-41,095,563

Other Liabilities:

$1.38M

Other Assets:

$1.41M

Cash:

$10.52M

Total Current Liabilities:

$3.23M

Property - Plant & Equipment:

$1.02M

Net Tangible Assets:

$17.95M

Total Current Assets:

$20.25M

Net Receivables:

$3.39M

Short-Term Investments:

$4.40M

Inventory:

$1.07M

Accounts Payable:

$571.46K

Short-Term Investments:

$4.40

Non Current Liabilities Total:

$1.95M

NXS Share Price History

NXS News

27 Apr, 2021
Next Science Limited (ASX:NXS) (Next Science / Company) is pleased to announce that it has received a section 510(k) clearance from the Food and Drug Administration (FDA) for the sale of XPERIENCE No Rinse Antimicrobial Solution as a medical device in the United States. Sales of XPERIENCE in the US will commence immediately.
09 Apr, 2021
While not a mind-blowing move, it is good to see that the Next Science Limited ( ASX:NXS ) share price has gained 12...
04 Mar, 2021
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
27 Jan, 2021
A look at the shareholders of Next Science Limited ( ASX:NXS ) can tell us which group is most powerful. Generally...
13 Dec, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
08 Dec, 2020
Next Science and 3M Donate $300,000 of Breakthrough Wound Treatment BlastX to Jacksonville-Area Charity Save A Leg Save A Life Foundation.
10 Nov, 2020
Next Science (ASX:NXS), an innovative medical technology company that is the leader in treating biofilm-based infections in humans, announced today that it has donated $300,000 worth of BlastX™ Antimicrobial Wound Gel to Hampton Ridge Healthcare and Rehabilitation in Toms River, New Jersey. This gift is part of a $500,000 donation program with 3M Company, the exclusive distributor of BlastX™, that helps caregivers treat patients suffering from chronic wounds at nursing and rehabilitative care facilities.
28 Oct, 2020
One thing we could say about the analysts on Next Science Limited (ASX:NXS) - they aren't optimistic, having just made...
27 Oct, 2020
Taking the occasional loss comes part and parcel with investing on the stock market. And unfortunately for Next...
08 Sep, 2020
One thing we could say about the covering analyst on Next Science Limited (ASX:NXS) - they aren't optimistic, having...
24 Jul, 2020
Today is shaping up negative for Next Science Limited (ASX:NXS) shareholders, with the analysts delivering a...
03 Jul, 2020
Next Science Limited's (ASX:NXS): Next Science Limited, a medical technology company, researches, develops, and...